Introducing the non-invasive prenatal test for trisomy 21 in Belgium: a cost-consequences analysis
Background The first- and second-trimester screening for trisomy 21 (T21) are reimbursed for all pregnant women in Belgium. Using a cut-off risk of 1:300 for T21, about 5% of all pregnant women are referred for definitive prenatal diagnosis using an invasive test, at a sensitivity of (only) 72.5%. T...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2014-11-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/4/11/e005922.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|